VideosApr 1, 2022White House Summit on Strengthening the Nation’s Early Warning System for Health Threats
Press ReleasesMar 23, 2022Thermo Fisher Scientific, Helix and Rosalind to Support National Program to Accelerate SARS-CoV-2 Variant Identification
ResearchMar 22, 2022Applying Implementation Science to Support the Success of a Precision Health Initiative in a Learning Health SystemACMG 2022
ResearchMar 22, 2022Integration of personalized medicine into primary care clinics: A path to make large scale population genomics studies successfulACMG 2022
NewsMar 18, 2022EXPLAINER: What to Know About the ‘Deltacron’ Hybrid Coronavirus VariantUS News & World Report
ResearchMar 15, 2022SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loadsCELL REPORTS MEDICINE
Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer CareAugust 7, 2025
Press ReleasesHelix Expands Pharmacogenomic Test Portfolio to Support Safer Cancer and Alzheimer’s TreatmentsMay 28, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer CareAugust 7, 2025
Press ReleasesHelix Expands Pharmacogenomic Test Portfolio to Support Safer Cancer and Alzheimer’s TreatmentsMay 28, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
